Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in peripheral spondyloarthritis without ankylosing spondylitis or psoriatic arthritis
NL-OMON32839Phase 2Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in peripheral spondyloarthritis (pSpA) comparing Humira then Humira with Placebo then Humira (2 arms). Primary endpoints: Patient's Global Assessment of Disease at week 12 and Safety. Planned start Nov 2008; status: not yet recruiting.
02
Drugs
03
Conditions
peripheral spondyloarthritis (pSpA)
Beyond the preview
Go deeper on NL-OMON32839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32839.